MX393880B - Co-cristales de compuestos de glicina sustituida y usos de los mismos. - Google Patents

Co-cristales de compuestos de glicina sustituida y usos de los mismos.

Info

Publication number
MX393880B
MX393880B MX2019009616A MX2019009616A MX393880B MX 393880 B MX393880 B MX 393880B MX 2019009616 A MX2019009616 A MX 2019009616A MX 2019009616 A MX2019009616 A MX 2019009616A MX 393880 B MX393880 B MX 393880B
Authority
MX
Mexico
Prior art keywords
crystals
substituted glycine
glycine compounds
compound
disorders
Prior art date
Application number
MX2019009616A
Other languages
English (en)
Spanish (es)
Other versions
MX2019009616A (es
Inventor
Ching- Cheng Wang
Guochuan Emil Tsai
Tien- Lan Hsieh
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2019009616A publication Critical patent/MX2019009616A/es
Publication of MX393880B publication Critical patent/MX393880B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62Three oxygen atoms, e.g. ascorbic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
MX2019009616A 2017-02-13 2018-01-11 Co-cristales de compuestos de glicina sustituida y usos de los mismos. MX393880B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/430,750 US9877942B1 (en) 2017-02-13 2017-02-13 Co-crystals of substituted glycine and uses thereof
PCT/CN2018/072186 WO2018145553A1 (en) 2017-02-13 2018-01-11 Co-crystals of substituted glycine compounds and uses thereof

Publications (2)

Publication Number Publication Date
MX2019009616A MX2019009616A (es) 2019-10-14
MX393880B true MX393880B (es) 2025-03-24

Family

ID=61005084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009616A MX393880B (es) 2017-02-13 2018-01-11 Co-cristales de compuestos de glicina sustituida y usos de los mismos.

Country Status (11)

Country Link
US (4) US9877942B1 (enExample)
EP (1) EP3579828B1 (enExample)
JP (2) JP2020507567A (enExample)
KR (1) KR20190118574A (enExample)
CN (1) CN110520117A (enExample)
CA (1) CA3051284A1 (enExample)
IL (1) IL268220B (enExample)
MX (1) MX393880B (enExample)
RU (1) RU2019128576A (enExample)
TW (1) TWI670058B (enExample)
WO (1) WO2018145553A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
CN113233976B (zh) * 2021-05-08 2021-11-16 广州萃普生物科技有限公司 一种没食子酸和氨基乙酸共晶及含有该共晶的美白膏霜
EP4419499A1 (en) 2021-10-20 2024-08-28 Purac Biochem B.V. Co-crystal of citric acid and glycine and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof

Also Published As

Publication number Publication date
TWI670058B (zh) 2019-09-01
IL268220B (en) 2022-04-01
JP7723991B2 (ja) 2025-08-15
US20180228753A1 (en) 2018-08-16
EP3579828B1 (en) 2025-03-26
US20190262299A1 (en) 2019-08-29
WO2018145553A1 (en) 2018-08-16
US20180228754A1 (en) 2018-08-16
JP2020507567A (ja) 2020-03-12
CA3051284A1 (en) 2018-08-16
EP3579828A1 (en) 2019-12-18
EP3579828A4 (en) 2020-11-18
IL268220A (en) 2019-09-26
MX2019009616A (es) 2019-10-14
RU2019128576A (ru) 2021-03-15
TW201840308A (zh) 2018-11-16
JP2023082101A (ja) 2023-06-13
RU2019128576A3 (enExample) 2021-05-14
CN110520117A (zh) 2019-11-29
US10765651B2 (en) 2020-09-08
US10328041B2 (en) 2019-06-25
US9877942B1 (en) 2018-01-30
KR20190118574A (ko) 2019-10-18
US10328042B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
ECSP18083519A (es) Inhibidores de bromodominios
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX388749B (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.
UY33357A (es) Uracilos herbicidas
MX375424B (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
UY32098A (es) Heteroarilos sustituidos
CR20170392A (es) Compuestos bicíclicos de sulfonamida cetona
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
MX391221B (es) Compuestos y composiciones y usos de los mismos.
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
MX393880B (es) Co-cristales de compuestos de glicina sustituida y usos de los mismos.
MX386616B (es) Compuestos de carfilzomib pegilados.
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
PE20170439A1 (es) Derivados de bis(aril)catecol como herbicidas
AR109022A1 (es) Mezclas activas como plaguicidas
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
EP3820980A4 (en) ESTERQUAT COMPOSITIONS